Skip to contentpdufa.bio

ARV-6723 (HPK1 degrader)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

ARV-6723 (HPK1 degrader) is an Arvinas, Inc. program in oncology (immuno-oncology). Its next catalyst is a Readout in Q4 2027.

ARVN catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: oncology (immuno-oncology). Sponsor: Arvinas, Inc. (ARVN). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027ARVN

Questions

When is ARV-6723 (HPK1 degrader)'s next FDA decision or readout?

The next tracked catalyst for ARV-6723 (HPK1 degrader) is a Readout in Q4 2027.

What happened at ARV-6723 (HPK1 degrader)'s most recent FDA decision?

No FDA decision for ARV-6723 (HPK1 degrader) is in our archive yet.

What is ARV-6723 (HPK1 degrader) used for?

In our records ARV-6723 (HPK1 degrader) is under review or in development for oncology (immuno-oncology).

Who makes ARV-6723 (HPK1 degrader)?

Arvinas, Inc. (ARVN).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.